Michael Schmainda, co-founder and CEO of IQ-AI Limited's (LON:IQAI) subsidiary Imaging Biometrics tells Proactive London's Andrew Scott they're developing a technology that could revolutionise the detection and treatment of brain tumours. IB CAD has been created to pick up cancer cells before they are visible on standard imaging. It does this by combining multi-parameter magnetic resonance data and artificial intelligence algorithms, and, in a structured way, it can pick up the tell-tale signs of the disease.
IQ-AI's Imaging Biometrics developing technology that could 'revolutionise brain tumour imaging'
Quick facts: IQ-AI Limited
Price: 4.85 GBX
Market Cap: £7.08 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE